Treating hematological malignancies and solid tumors
The company’s lead therapeutic candidate, obe-cel, met its primary endpoint at an interim analysis of the pivotal phase 2 FELIX study for adult ALL. Additional data is expected in mid-2023 with a BLA submission to the US FDA planned by the end of 2023.
The opportunity for obe-cel extends beyond adult ALL. Obe-cel is currently being investigated in ongoing clinical studies for B-NHL indications and pediatric ALL. Alongside obe-cel, Autolus is progressing a number of pipeline assets both in preclinical and clinical development across hematological malignancies and solid tumors.
The novel fast off rate CAR in obe-cel drives T cell activity and long-term persistence in the absence of severe immunotoxicityFind out more
Autolus are applying our extensive cell programming capability to develop product candidates across hematological malignancies and solid tumors.Read more